Otsuka Pharmaceutical will pay $100m up front for ADHD technology developer Neurovance, which had raised $27m in equity from investors including Novartis.

The university has partnered healthcare provider Carilion Clinic to establish a $15m fund focused on the local area.

Merck KGaA and Qualcomm have put money into Medisafe, which is aiming to solve the problem of patients not adhering to their medication.

The disease detection technology developer has received cash from a consortium that included GV.

Illumina spinout Grail has raised a first tranche of its series B round, thanks to investors including Johnson & Johnson, as it targets a second close of up to $1.8bn.

Cambridge Innovation Capital has backed the series B round, alongside other investors that included Parkwalk Advisors.

Osage University Partners has taken part in a series B round for PMV Pharmaceuticals.

The transaction was supported by Manipal Education and Medical Group and state-owned CDC Group.